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Abstract
Purpose Peptide receptor targeting has become an increas-
ingly attractive method to target tumors diagnostically and
radiotherapeutically. Peptides linked to a variety of chelators
have been developed for this purpose. They have, however,
rarely been tested for their agonistic or antagonistic properties.
We report here on a somatostatin antagonist that switched to
an agonist upon coupling to a DOTA chelator.
Methods Two novel somatostatin analogs, 406-040-15 and
its DOTA-coupled counterpart 406-051-20, with and without
cold Indium labeling, were tested for their somatostatin
receptor subtypes 1–5 (sst1–sst5) binding affinity using
receptor autoradiography. Moreover, they were tested
functionally for their ability to affect sst2 and sst3
internalization in vitro in HEK293 cells stably expressing
the human sst2 or sst3 receptor, using an immunofluores-
cence microscopy-based internalization assay.
Results All three compounds were characterized as pan-
somatostatin analogs having a high affinity for all five sst. In
the sst2 internalization assay, all three compounds showed
an identical behavior, namely, a weak agonistic effect
complemented by a weak antagonistic effect, compatible
with the behavior of a partial agonist. Conversely, in the
sst3 internalization assay, 406-040-15 was a full antagonist
whereas its DOTA-coupled counterpart, 406-051-20, with
and without Indium labeling, switched to a full agonist.
Conclusion Adding the DOTA chelator to the somatostatin
analog 406-040-15 triggers a switch at sst3 receptor from an
antagonist to an agonist. This indicates that potential
radioligands for tumor targeting should always be tested
functionally before further development, in particular if a
chelator is added.
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Introduction
Somatostatin receptor targeting of tumors has been shown
to be a highly successful new method for the diagnosis and
radiotherapy of neuroendocrine tumors [1–3]. A prerequi-
site for that is not only a high density of receptors in the
tumors but also the availability of somatostatin radioligands
optimized for such investigation.
To obtain suitable radiolabeled tracers, one of the
successful strategies of research followed in recent years
in nuclear medicine and radiochemistry was to link peptide
ligands that were selected for tumor targeting to specific
chelator molecules [2–5]. Such chelators have included N4
and HYNIC molecules that will be preferably used for
99mTc imaging, or DTPA and DOTA molecules that can
chelate radionuclides such as 111In, 90Y, 177Lu, or 68Ga.
Since these chelators are relatively large molecules, the
peptide-chelator conjugate did often lose some of its
receptor binding affinity; therefore, it has always been a
prerequisite to confirm that the compounds retain high
affinity receptor binding before further development. The
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great variety of radionuclides to choose from gives a wide
flexibility to optimize diagnosis and therapy of tumor
targets [4]. This synthetic approach has been highly
successful for chelator-coupled peptide radioligands de-
rived from various peptides, including somatostatin, bomb-
esin, cholecystokinin, or glucagon-like peptide-1 [4–9].
While candidate compounds have always been tested for
their high affinity binding properties in order to make a
proper selection of the most suitable ones, it is only recently
that scientists became aware that not only the binding but
also the functional profile of these analogs might be of
importance, in particular to know if the radioligands are
agonists or antagonists [10]. According to recent studies
[11–13], both agonist and antagonist radioligands may be
suitable for in vivo tumor targeting, but for completely
different cell biological and molecular reasons.
After binding to the receptor, radioactive agonists are
actively taken up into the cells by the receptor as a receptor-
ligand complex. In this way the agonist can accumulate
within the cell giving a strong radiation signal [12].
Receptor-mediated radioligand internalization is a power-
ful, specific, and reversible mechanism that represents the
molecular basis for successful peptide receptor targeting in
vivo [12]. Importantly, somatostatin receptor internalization
appears to be only inducible by somatostatin agonists, but
not by somatostatin antagonists [10, 12].
However, it was observed recently that peptide receptor
targeting in vivo could also be successful without internali-
zation of the receptor-ligand complex [11, 13]. In this case it
is necessary to use antagonists rather than agonists; they will
also bind with high affinity to the receptor as agonists do, but
will not elicit receptor internalization or second messenger
activation by themselves [11, 13]. Such antagonists appear to
be good in vivo tracers because they bind to more receptor
sites than agonists and dissociate more slowly than agonists,
giving also a strong and possibly long-lasting radiation
signal [11]. Radioligand antagonists are therefore increas-
ingly being developed in recent times [13–15].
In the present study, we give an example of a
somatostatin antagonist that switches its pharmacological
profile to an agonist, when linked to a DOTA chelator. This
example demonstrates that one cannot predict a priori
whether a structurally modified radioligand, including the
addition of a chelator, activates or antagonizes the receptor
internalization process.
Materials and methods
Synthesis
Peptides were synthesized by the solid-phase approach on a
CS-Bio Peptide Synthesizer (Model CS536). Three equiv-
alent excess of Boc-amino acid (1.2 mmol) based on the
original substitution of the resin was used for each
coupling. Peptide couplings were mediated for 1 h by
DIC/HOBt (1.2 mmol/1.8 mmol) in N,N-dimethylforma-
mide (DMF). Boc removal was achieved with trifluoro-
acetic acid (TFA) (60% in CH2Cl2, 1–2% ethanedithiol or
m-cresol) for 20 min. An isopropyl alcohol (1% m-cresol)
wash followed TFA treatment and then successive washes
with triethylamine (TEA) solution (10% in CH2Cl2),
methanol, triethylamine solution, methanol, and CH2Cl2
completed the neutralization sequence. The completed
peptides were unprotected and cleaved from the resin by
anhydrous HF containing the scavengers anisole (10% v/v)
and methyl sulfide (5% v/v) for 60 min at 0°C. The diethyl
ether-precipitated crude peptides were cyclized in 75%
acetic acid (200 ml) by addition of iodine (10% solution in
methanol) until the appearance of a stable orange color.
Forty minutes later, ascorbic acid was added to quench the
excess of iodine. For the synthesis of the DOTA-peptide
conjugate (406-051-20) the side chain of Lys9 (SRIF
numbering) was protected with the Fmoc protecting group
that stays on after HF cleavage. The solution of DOTA-
NHS ester (38 mg, 48 µM) in DMF (160 µl) and N,N′-
diisopropylethylamine (DIPEA) (40 µl, 24 µM) was added
to the solution of the RP-HPLC purified [Lys(Fmoc)]9
analog (∼20 µM) in dry DMF (800 µl). The mixture was
stirred at room temperature for 5 h. The progress of the
reaction was followed by analytical HPLC. After comple-
tion of the reaction, a preparative RP-HPLC purification
was performed yielding the pure DOTA-[Lys(Fmoc)]9
analog. Removal of the Fmoc protecting group from the
Lys side chain was achieved with 20% piperidine/DMF
solution resulting in the DOTA-coupled analog, which was
further purified by preparative RP-HPLC. The purity of the
final peptides determined by analytical RP-HPLC and
capillary zone electrophoresis (CZE) was greater than
95%. Mass spectra (MALDI-MS) were measured on an
ABI-Perseptive DE-STR instrument. The observed mono-
isotopic (M+H)+ values of both peptides corresponded with
the calculated (M+H)+ values.
In-DOTA analog
The Indium complex formation was carried out according
to published procedures [16]. A mixture of 3.04 mg
(∼14.8 µM) 406-051-20 in 6 ml of 0.2 M ammonium
acetate buffer (pH 5) was heated with 500 μl of a solution
containing 2.01 mg InCl3 in 930 µl of 0.2 M ammonium
acetate buffer (pH 5) at 95°C for 40 min. The complex
formation was followed by analytical HPLC (C18 Vydac
TP 254 column, eluents: A=0.1% TFA in water and B=
60% acetonitrile in A; gradient: 40% B to 80% B in 40 min.
The new product eluted at 68.5% B while the starting
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material eluted at 66.0% B. After 40 min heating the
reaction was complete, the solution was cooled to room
temperature, and the pH of the solution was adjusted to
acidic with trifluoroacetic acid. Purification of the peptide
complex was performed by preparative HPLC affording
1.8 mg (56%) of product In-406-051-20 with a purity of
97% determined by CZE and HPLC. The observed
monoisotopic [M+H]+ 2,169.70 corresponded with the
calculated [M+H]+ 2,069.75.
Reagents
All reagents were of the best grade available and were
purchased from common suppliers. The somatostatin
receptor subtype 2 (sst2)-specific antibody R2-88 was
provided by Dr. Agnes Schonbrunn (Houston, TX, USA)
and the sst3-specific antibody (SS-850) was purchased from
Gramsch Laboratories (Schwabhausen, Germany). The
secondary antibody Alexa Fluor 488 goat anti-rabbit IgG
(H+L) was from Molecular Probes, Inc. (Eugene, OR,
USA). SS-28 and the somatostatin analogs 406-040-15,
406-051-20, and In-406-051-20 were synthesized at the
Salk Institute. [Tyr3]-octreotide (TOC) was from Novartis
(Basel, Switzerland).
Cell lines
The HEK293 cell lines expressing either the T7-epitope
tagged human sst2 receptor (HEK-sst2) or the human sst3
receptor (HEK-sst3) were cultured at 37°C and 5% CO2 in
DMEM containing 10% fetal bovine serum (FBS), 100 U/
ml penicillin, 100 μg/ml streptomycin, and 500 μg/ml
G418 [10]. All culture reagents were from Gibco BRL, Life
Technologies (Grand Island, NY, USA).
Receptor autoradiography
Cell membrane pellets were prepared from human sst1-
expressing CHO cells, sst2-, sst3-, sst4-expressing CCL39
cells, and sst5-expressing HEK293 cells and stored at −80°C.
Receptor autoradiography was performed on 20-μm thick
cryostat (Microm HM 500, Walldorf, Germany) sections of
the membrane pellets, mounted on microscope slides, and
then stored at −20°C as previously described [14, 17]. For
each of the tested compounds, complete displacement
experiments with the universal somatostatin radioligand
[Leu8, D-Trp22, 125I-Tyr25]-SS-28 (125I-[LTT]-SS-28)
(2,000 Ci/mmol; Anawa, Wangen, Switzerland) using
15,000 cpm/100 μl and increasing concentrations of the
unlabeled peptide ranging from 0.1 to 1,000 nM were
performed. As control, unlabeled SS-28 was run in parallel
using the same increasing concentrations. The sections were
incubated with 125I-[LTT]-SS-28 for 2 h at room temperature
in 170 mmol/l Tris-HCl buffer (pH 8.2), containing 1%
bovine serum albumin (BSA), 40 mg/l bacitracin, and
10 mmol/l MgCl2 to inhibit endogenous proteases. The
incubated sections were washed twice for 5 min in cold
170 mmol/l Tris-HCl (pH 8.2) containing 0.25% BSA. After
a brief dip in 170 mmol/l Tris-HCl (pH 8.2), the sections
were dried quickly and exposed for 1 week to Kodak
BioMax MR film. IC50 values were calculated after
quantification of the data using a computer-assisted
image processing system as described previously [18].
Tissue standards (autoradiographic [125I] and/or [14C]
microscales, GE Healthcare, Little Chalfont, UK) that
contain known amounts of isotope, cross-calibrated to
tissue-equivalent ligand concentrations were used for
quantification [14, 19].
Immunofluorescence microscopy
Immunofluorescence microscopy-based internalization
assay for sst2 and sst3 was performed as previously
described [10]. HEK-sst2 or HEK-sst3 cells were grown
on poly-D-lysine (20 μg/ml) (Sigma-Aldrich, St. Louis,
MO, USA) coated 35-mm four-well plates (Cellstar,
Greiner Bio-One GmbH, Frickenhausen, Germany). To
distinguish whether the tested analogs are agonists or
antagonists in respect of stimulating receptor internaliza-
tion, HEK-sst2 cells or HEK-sst3 cells were treated for
30 min at 37°C in growth medium, either with vehicle
alone (negative control), or, as positive control, with TOC
(HEK-sst2) or SS-28 (HEK-sst3) at concentrations ranging
between 10 nM and 10 μM, or with 10 nM TOC (HEK-
sst2) or 100 nM SS-28 (HEK-sst3) in the presence of an
excess (10 μM) of the somatostatin analogs, or with the
somatostatin analogs alone at concentrations ranging
between 10 nM and 10 μM when the analogs are tested
for agonism. The cells were then rinsed twice with PS
(100 mM phosphate buffer containing 0.15 M sucrose),
fixed and permeabilized for 7 min with cold methanol
(−20°C), rinsed twice with PS, and then blocked for
60 min at room temperature with PS containing 0.1%
BSA. Subsequently, the cells were incubated for 60 min at
room temperature either with the sst2- or sst3-specific
primary antibodies R2-88 or SS-850, respectively, diluted
1:1,000 in PS and then washed 3 times for 5 min with PS
containing 0.1% BSA. The cells were then incubated for
60 min at room temperature in the dark with the
secondary antibody Alexa Fluor 488 goat anti-rabbit IgG
(H+L) diluted in PS (1:600), subsequently washed 3 times
for 5 min each with PS containing 0.1% BSA, and
embedded with PS/glycerol 1:1 and covered with a glass
cover slip. The cells were imaged using a Leica DM RB
immunofluorescence microscope and an Olympus DP10
camera.
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Results
In the course of a search for novel somatostatin antagonists,
we designed and synthetized the dodecapeptide 406-040-15
as well as its DOTA-coupled counterpart 406-051-20
(Fig. 1). Both compounds, as well as the In-labeled 406-
051-20, were tested for their sst1–sst5 binding profile in
transfected cells stably expressing the human sst1–sst5. All
three compounds show a “pan-somatostatin” binding pro-
file, namely, a high affinity binding to all five somatostatin
receptor subtypes (Table 1). While the DOTA-containing
analog 406-051-20 has higher IC50 values, in particular at
sst2 and sst3 (Table 1), the In-labeled 406-051-20 has the
lowest IC50 values of all three compounds.
Internalization assays are suitable assays to test for
functional responses of somatostatin analogs as receptor
targeting drugs, in particular when they are foreseen to
become efficient tumor imaging agents. Among the five sst,
two of them (sst2 and sst3) are well known for their
prominent ability to internalize after agonist stimulation
[20, 21].
The three compounds were therefore tested first in vitro in
HEK-sst2 cells for their agonistic and antagonistic proper-
ties at the sst2 receptor with an immunofluorescence-based
internalization assay. This type of assay allows first to
evaluate the agonistic efficacy of a compound to trigger
receptor internalization when the compound is given alone.
If the tested compound shows poor or no efficacy in this
assay, it will be tested in a further setting that allows one to
distinguish between an inefficient agonist and an antago-
nist; indeed, when given in excess together with a reference
agonist (i.e., natural SS-28 or TOC), the compound will be
identified as antagonist if it is able to dose-dependently
block the receptor internalization triggered by the reference
agonist [10, 12]. As seen in Fig. 2, all three compounds,
406-040-15, 406-051-20, and In-406-051-20, were able to
induce sst2 internalization; however, a relatively high dose
(10 μM) was needed to induce a weak effect. All three
Fig. 1 Structure of 406-040-15 and 406-051-20. 406-040-15: cyclo
(2–11) H-Cpa-DCys-Asn-Phe-Phe-DTrp-Lys-Thr-Phe-Thr-Cys-2Nal-
NH2. 406-051-20: cyclo(2–11) DOTA-Cpa-DCys-Asn-Phe-Phe-
DTrp-Lys-Thr-Phe-Thr-Cys-2Nal-NH2. Cpa: 4-Cl-phenylalanine.
DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
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compounds were also tested in the presence of TOC, in
order to see if they can antagonize TOC-induced receptor
internalization. As seen in Fig. 2, the three compounds had
a comparable behavior in this assay as well, namely, a
minor inhibitory effect on the TOC-induced sst2 internali-
zation. All three compounds are therefore likely to act as
partial agonists at sst2 receptor.
The three compounds were also tested functionally for
their agonistic or antagonistic properties at the sst3 receptor
(Figs. 3 and 4) using an immunofluorescence-based sst3
receptor internalization assay [10], an assay comparable to
the one used for sst2 internalization. In the absence of
peptide (negative control), a strong membrane staining of
HEK-sst3 cells is detectable using a sst3-specific antibody
(Fig. 3) [10]. In the presence of the agonist SS-28, used as
positive control, the sst3 receptor is efficiently internalized
in a dose-dependent manner (Fig. 3). In contrast, the
dodecapeptide 406-040-15 has no effect alone on sst3
internalization (Fig. 4) even at a high concentration of
10 μM. However, when it is applied at the same
concentration in the presence of 100 nM SS-28, it abolishes
the SS-28-triggered sst3 internalization completely and
therefore acts as a competitive antagonist (Fig. 4). This is
in contrast to the DOTA-containing analog 406-051-20 and
Compounds sst1 sst2 sst3 sst4 sst5
SS-28 2.0±0.2 (6) 2.1±0.2 (6) 1.8±0.4 (6) 2.0±0.3 (6) 2.8±0.4 (3)
406-040-15 2.1±0.6 (3) 6.7±1.2 (3) 9.6±2.1 (3) 5.3±0.7 (3) 9.0±1.6 (3)
406-051-20 8.9±1.9 (3) 25±6.1 (3) 29±6.7 (3) 5.8±1.0 (3) 15±1.0 (3)
In-406-051-20 1.5±0.1 (3) 2.9±0.6 (3) 14±0.7 (3) 2.1±0.1 (3) 3.3±0.3 (3)
Table 1 sst1–sst5 affinity pro-
file of the three somatostatin
analogs compared to SS-28 as
reference
Data expressed as IC50 in nM
(mean±SEM; n=number of
experiments in parentheses)
vehicle
(neg. control)
10 nM TOC
(pos. control)
10 nM TOC
+
10 µM 406-040-15
10 nM TOC
+
10 µM 406-051-20
10 µM 406-040-15
10 µM 406-051-20
10 nM TOC
+
10 µM In-406-051-20
10 µM In-406-051-20
Fig. 2 sst2 internalization
assay to determine whether 406-
040-15, 406-051-20, and In-
406-051-20 are agonists or
antagonists. HEK-sst2 cells were
treated either with vehicle
(negative control), with 10 nM
TOC, a concentration inducing a
submaximal internalization
effect (positive control), or with
10 μM 406-040-15, 406-051-20,
or In-406-051-20 in the absence
or presence of 10 nM TOC.
Following incubation with the
peptides, the cells were pro-
cessed for immunocytochemis-
try as described in the
“Materials and methods”
section. All three analogs, 406-
040-15, 406-051-20, and
In-406-051-20, act as weak
agonists but are also able to
partially antagonize TOC-
induced sst2 internalization
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its In-labeled correspondent, which are both able to dose-
dependently trigger internalization of the sst3 receptors
(Fig. 3). When given together with SS-28, both compounds,
In-labeled and unlabeled 406-051-20, do not antagonize the
SS-28-induced effect (Fig. 3). 406-051-20, with and
without metal, is therefore a full agonist with respect to
sst3 internalization.
Discussion
We describe here the complex effects on sst2 and sst3
internalization after adding a chelator like DOTA to a
somatostatin analog. In the present study, we have focused
on receptor internalization, because it has been considered a
relevant functional parameter for tumor radiotargeting and
for nuclear medicine. Indeed, an efficient internalization of
the receptor-ligand complex is necessary in order to allow a
radioligand, after binding to the receptor, to be specifically
transported into the cells and to accumulate within the
tumor cells. There are basically two ways to investigate
internalization in vitro: one approach is to use the
radioactive ligand and to follow the kinetics of its uptake
into the cells [21]. The other approach is to use the
nonradioactive ligand and evaluate its effects on the
internalization of the receptor itself, by detecting receptor
trafficking by immunofluorescence microscopy [10]. The
second approach can allow us to differentiate pharmaco-
10 µM1 µM100 nM10 nM
10 µM1 µM100 nM10 nM
vehicle
(neg. control)
100 nM SS-28
+
10 µM 406-051-20
10 µM1 µM100 nM10 nM
100 nM SS-28
+
10 µM In-406-051-20
406-051-20
In-406-051-20
SS-28
Fig. 3 sst3 internalization assay showing the agonistic properties of
406-051-20 and In-406-051-20. HEK-sst3 cells were treated either
with 406-051-20, In-406-051-20, or SS-28 at concentrations ranging
between 10 nM and 10 μM, or with vehicle alone (negative control).
To test for antagonism, HEK-sst3 cells were treated with 10 μM 406-
051-20 or In-406-051-20 in the presence of 100 nM SS-28. Following
incubation with the peptides, the cells were processed for immunocy-
tochemistry as described in the “Materials and methods” section.
While 406-051-20 and In-406-051-20 act as agonists stimulating sst3
internalization, they are not able to antagonize SS-28-induced sst3
internalization
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logically if the compound acts as an agonist or an
antagonist. This was therefore the method of choice for
this study.
The three compounds of interest were characterized in
binding experiments as pan-somatostatin analogs, with high
affinity binding to all somatostatin receptor subtypes. We
have focused on sst2 and sst3 internalization since these are
the only two somatostatin subtypes found to have a most
efficient receptor internalization capability [20].
The three compounds do not differ significantly in their
capacity to induce sst2 internalization. They all have agonistic
properties and are relatively weak agonists when compared
with TOC. Since they show, in addition, a weak antagonistic
behavior to inhibit the sst2 internalization induced by TOC,
all three can be considered partial agonists. Therefore, in the
sst2 system, adding DOTA or In-DOTA to 406-040-15 does
not change the functional characteristics of this compound in
respect to sst2 internalization.
The situation is completely different for sst3. The
DOTA-free analog 406-040-15 is a full and competitive
antagonist at sst3, while the DOTA-containing 406-051-20,
with or without Indium, switches completely to an agonist
in the sst3 receptor internalization assay. This impressive
switch in biological function after the addition of a chelator
is unexpected and is, at the moment, hard to explain and to
understand from a structural point of view. In general, the
conversion of a peptide agonist to a peptide antagonist has
indeed been so far an empirical tour de force involving such
modifications as deletions or the introduction of unnatural
amino acids with different chirality. For sst2, inverting
chirality at position 2 and 3 of octreotide (H-DPhe2-c[Cys3-
Phe7-DTrp8-Lys9-Thr10-Cys14]-Thr15-ol, SS-14 numbering)
was reported to be the key structural modification convert-
ing a somatostatin agonist into a full competitive antagonist
at sst2 [22]. For sst3, and as follow-up of the present
observation, further investigations may lead to a better
understanding of structural requirements for agonism/
antagonism. To our knowledge this is the first example of
a peptide antagonist of an hypothalamic releasing factor
(thyrotropin-releasing hormone, gonadotropin-releasing
hormone, growth hormone-releasing hormone, and
corticotropin-releasing hormone) or release inhibiting factor
(somatostatin) being switched back to an agonist upon
additional substitutions. It has been assumed that peptide
competitive antagonists are generated from agonists by
limiting the number of available conformations of the
agonist or by impeding a conformational change responsi-
ble for receptor activation. Lacking structural information at
this point, any interpretation of the data would be
speculative. NMR studies have been initiated to shed light
on this unusual observation.
Structural modifications of a compound after adding a
chelator may affect its biological characteristics in several
ways: one possibility, having the most dramatic consequen-
ces, is the one seen in the present study at the sst3 receptor
where a complete switch of biological activity is induced.
One other possibility, having no biological consequences, is
seen in the present study for the sst2 receptor. Between
these two extremes, there are other possible functional
changes, ranging from partial agonistic to inverse agonistic
activities. These latter functional changes may also affect
the radioligand uptake capacity in tumor cells. Indeed, it is
known in other systems for instance that partial agonists are
much less capable of promoting receptor internalization
than full agonists [23, 24].
In-labeled 406-051-20 has a pan-somatostatin binding
profile, but despite its high sst2 affinity, has, as partial
agonist, poor sst2 internalization characteristics and is
therefore unlikely to become a promising targeting tracer
for sst2-expressing tumors. These characteristics make In-
vehicle
(neg. control)
100 nM SS-28
(pos. control)
10 µM 406-040-15
100 nM SS-28
+
10 µM 406-040-15
Fig. 4 sst3 internalization assay
showing the antagonistic prop-
erties of 406-040-15. HEK-sst3
cells were treated either with
vehicle (negative control), with
100 nM SS-28, a concentration
inducing a submaximal internal-
ization effect (positive control),
or with 10 μM 406-040-15 in
the absence or presence of
100 nM SS-28. While 406-040-
15 alone is not able to stimulate
sst3 internalization, it does effi-
ciently antagonize SS-28-
induced sst3 internalization
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labeled 406-051-20 very much comparable to two other
pan-somatostatins, KE108 and SOM230, that have been
shown previously to have inadequate sst2 targeting proper-
ties [21, 25].
Before the availability of the recent biological data which
showed a role for receptor antagonists in tumor targeting [11,
13], it was considered sufficient to characterize a potential
tumor targeting compound by its receptor binding ability
and its in vivo tumor uptake properties as radioligand [6–8].
Agonist/antagonist profiles were not, or were only rarely,
investigated. Even recently, there have been examples of
studies where a DOTA-containing radioligand was consid-
ered an antagonist on the basis of sequence homology with
its nonchelated peptide, without having been tested itself
for antagonism [26], simply assuming that the addition of
the chelator would not modify the biological characteristics
of the original compound. The main message of this study
is therefore to recommend that potential new radioligands
for tumor targeting should be extensively tested function-
ally before further development, even after minor modifi-
cations such as the addition of a chelator.
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